Release Of Oxytocin In Response Research Articles

Release of oxytocin, prolactin and cortisol in response to extraordinary suckling

The aim of this trial was to clarify whether suckling after several weeks of only machine milking can affect the release of oxytocin, cortisol and prolactin in dairy cows. In total twelve Brown Swiss cows on their first to third lactation were used. Pre-experimental period: all cows were suckled three times daily (9.00, 14.00 and 20.00) and milked twice daily (7.00 and 17.30) in tie housing during the first 5 days postpartum. Afterwards the calves were separated and moved to another building. The cows were moved to loose housing and milked in the dairy parlour within the same stable. Experimental period: after four weeks of only machine milking twice daily, cows were relocated from the herd to the same place as they were housed and milked during their postpartum period. The cows were again suckled on day 3 and 4 after relocation at the same time as above. Oxytocin, cortisol and prolactin levels were evaluated during the first suckling on day 3 (9.00) and during suckling at the same time next day (4th suckling) after relocation. Oxytocin secretion was clearly inhibited in all cows during the first five minutes of suckling with tendency of slow increase during the next minutes of suckling (suckling lasted about 10 min) except for two primiparous cows showing an increase of oxytocin release from the first minute of suckling. The release of oxytocin in response to the 4th suckling significantly increased immediately after start of suckling. Both, cortisol and prolactin significantly increased in response to all sucklings. There were significantly higher prolactin and lower cortisol values during the first suckling as compared with the fourth suckling in primiparous but not in multiparous cows.

Verapamil prevents withdrawal excitation of oxytocin neurones in morphine-dependent rats

We investigated whether the full expression of morphine withdrawal excitation by supraoptic nucleus (SON) oxytocin neurones is a property of the neurones themselves or a partial function of their afferent inputs, by interrupting synaptic input activity via central administration of the L-type Ca 2+ channel blocker verapamil. In morphine-dependent rats, withdrawal-induced release of oxytocin from the posterior pituitary was suppressed by prior administration of intracerebroventricular (i.c.v.) verapamil (160 μg), as was release of oxytocin within the SON measured by microdialysis. During morphine withdrawal the increased electrical activity of SON neurones was also reduced both by i.c.v. verapamil and microdialysis application of verapamil or nifedipine into the SON. Oxytocin secretion evoked by electrical stimulation of the pituitary stalk was unaffected by i.c.v. verapamil suggesting a central site of action. To determine whether the inhibitory actions of verapamil were specific to morphine withdrawal, we also investigated the effects of verapamil on other oxytocin-secreting stimuli. I.C.V. verapamil given to morphine-naı̈ve rats abolished pituitary oxytocin release in response to activation of brainstem or rostral excitatory inputs by cholecystokinin (20 μg kg −1, i.v.) and 1.5 M saline (4 ml kg −1, i.p.) respectively, whilst in lactating rats, i.c.v. verapamil reduced suckling-induced release of oxytocin within the SON. These results suggest that verapamil has a central site of action on stimulated oxytocin release (including an action within the SON) and that both pre and post-synaptic L-type Ca 2+ channels are required for the full expression of morphine withdrawal in SON oxytocin neurones.

Effects of morphine and naloxone on the release oxytocin and on milk ejection in dairy cows.

The aim of this study was to investigate the action of opioids (the mu receptor agonist morphine) and the antagonist naloxone on inhibition of oxytocin release and milk let-down in response to milking in dairy cows. In the first experiment, cows were injected with 0, 21, 70 and 210 mg morphine 10 min before milking on four successive days. Plasma oxytocin levels after 1 min manual stimulation of the udder were reduced by 70 and 210 mg morphine, and milk let-down was inhibited at the latter dose. In the second experiment, cows were injected after a control milking with 210 mg morphine (or 350 mg at 10 min before milking the following day if not effective) to inhibit milk flow. On the following day the inhibiting dose of morphine was given with 210 mg naloxone. Naloxone injection given before morphine had no effect on plasma oxytocin concentrations, but abolished the inhibition of oxytocin release by morphine and potentiated oxytocin release in response to milking. Naloxone alone injected the day after control milking increased oxytocin levels during milking, suggesting involvement of the opioid system in milking. A model has been developed for the control of opioid effects during milking. Morphine suppressed oxytocin release during milking in a dose-dependent manner and the effect was reversible by naloxone.

Alcohol Inhibits Suckling-Induced Oxytocin Release in the Lactating Rat

Oxytocin release in response to suckling was examined in primiparous lactating rats following alcohol administration. Lactating rats, with litters adjusted to eight pups on day 2, were implanted with an atrial catheter between days 6 to 8 of lactation. Four days later, alcohol in doses 0.0, 1.0, or 2.0 g/kg BW was infused, and blood alcohol levels achieved following infusion of initial doses were maintained for 4 h. On the day of alcohol infusion, pups were separated from the dams at 8:00 a.m. Following completion of alcohol infusion, a baseline blood sample was obtained, pups were returned to the dams, and additional samples were obtained 5, 10, 30, and 60 min after suckling started. Oxytocin levels in plasma were determined by radioimmunoassay. Suckling latencies and milk consumption during the 60 min of suckling were determined. Alcohol administration inhibited suckling-induced oxytocin release across all time points. Suckling latencies among groups were comparable. Milk consumption by pups during the 60 min of suckling was lower for the alcohol administered groups. The data from the present study demonstrate that acute alcohol administration to lactating rats inhibits suckling-induced oxytocin release resulting in reduction of milk secretion.

Role of NO on vasopressin and oxytocin release and blood pressure responses during osmotic stimulation in rats.

NG-nitro-L-arginine methyl ester (L-NAME, 250 micrograms/5 microliters), an inhibitor of nitric oxide (NO) synthase, or artificial cerebrospinal fluid (5 microliters) was administered intracerebroventricularly to conscious naive rats or to rats treated subcutaneously (15 microliters/kg) with NaCl (0.15, 0.45, or 1.0 M) or given a needle prick only. Intracerebroventricular injection of L-NAME increased plasma concentration of vasopressin (VP) and oxytocin (OT) in control naive rats, indicating that NO tonically inhibits basal secretion of both hormones during isosmotic isovolemic conditions. Osmotic stimulation with hypertonic saline (0.45 and 1.0 M NaCl) elevated plasma levels of both hormones as expected. Central blockade of NO synthase further enhanced secretion of OT during mild, but not strong, osmotic stimulation, whereas the high levels of VP remained unaffected by L-NAME. In animals treated with the needle prick or 0.15 M NaCl, only OT levels were increased after L-NAME. Therefore, NO selectively inhibits OT release in response to a painful stimulus (needle prick) and moderate osmotic stimulation to promote a preferential release of VP. A transient pressor response was observed after subcutaneous injection of 0.15 and 0.45 M NaCl, but a sustained response was obtained after 1.0 M NaCl. Regardless of whether the animals received NaCl solutions, however, treatment with L-NAME elevated blood pressure in all animals. Thus NO-induced vasodilation maintains basal arterial blood pressure and limits the pressor response to osmotic stimulation.

Kappa-Opioid Restraint of Oxytocin Secretion: Plasticity through Pregnancy

Oxytocin neurone terminals display a powerful opioid-mediated auto-inhibitory mechanism which restrains secretory activity. In pregnancy, upregulation of this mechanism may underlie the accumulation of large stores of oxytocin in the pituitary. In the present study, conscious pregnant rats were cannulated to allow blood samples to be taken for measurement of oxytocin secretion in response to intravenous administration of cholecystokinin (CCK). In each rat, we measured the secretory response to CCK before and after administration of norbinaltorphine (norBNI), a selective kappa-opioid antagonist, or of naloxone, a relatively mu-selective antagonist. Throughout pregnancy, the stimulatory effect of CCK was enhanced by prior administration of norBNI. In pregnant rats norBNI also consistently increased basal oxytocin secretion, while naloxone had no effect, suggesting that in pregnancy there is active restraint of oxytocin secretion by endogenous opioids acting at kappa-receptors. However, in late pregnancy, between days 17 and 20, there was a significant reduction in the efficacy of norBNI in potentiating the oxytocin release in response to CCK, compared to its efficacy either in non-pregnant rats or in rats between days 8 and 13 of pregnancy. This suggests that in late pregnancy, endogenous kappa-opioid restraint is downregulated. In addition, the present results demonstrate an attenuation in the potency with which CCK evoked oxytocin release in late pregnancy. The attenuation was unrelated to opioid restraint at the level of the pituitary since it coincided with apparent desensitization of this auto-inhibitory mechanism.

Presynaptic actions of morphine: blockade of cholecystokinin-induced noradrenaline release in the rat supraoptic nucleus.

1. This study aimed to establish the site at which morphine acts to inhibit oxytocin release in response to peripheral administration of cholecystokinin (CCK). 2. Conscious rats were given morphine or vehicle followed by CCK or vehicle (I.V.). Fos immunoreactivity was apparent 90 min after CCK injection in the supraoptic nucleus of vehicle- but not morphine-pretreated animals. 3. In the dorsomedial (C2/A2) and the ventrolateral (C1/A1) regions of the brainstem, about half of the cells immunoreactive for tyrosine hydroxylase (TH) expressed Fos-like protein after CCK injection. In the C2/A2 region, 20% of the Fos-positive cells also showed TH immunoreactivity, whereas in the C1/A1 region 68% did so. Morphine treatment did not significantly change the number of cells expressing Fos immunoreactivity, or the percentage of TH-positive cells expressing Fos-like protein. 4. Amine release was measured in the supraoptic nucleus of urethane-anaesthetized rats using a microdialysis probe. An I.V. injection of CCK increased the concentrations in the dialysate of noradrenaline and serotonin, but not of either adrenaline or dopamine. Pretreatment with morphine (I.V.) blocked the effects of CCK in a naloxone-reversible manner. 5. Inclusion of morphine in the dialysate also blocked the increase in noradrenaline and serotonin in response to CCK in a naloxone-reversible manner. 6. These observations indicate that morphine acts near or within the supraoptic nucleus to block CCK-evoked noradrenaline release presynaptically. This presynaptic action of morphine may be a cause of the blockade of oxytocin release after CCK.

Stimulation of oxytocin release within the supraoptic nucleus and into blood by CCK-8.

Simultaneous microdialysis in brain and blood was used to monitor the effects of systemic and central cholecystokinin octapeptide (CCK-8) on the release of oxytocin and vasopressin within the hypothalamic supraoptic nucleus (SON) as well as into blood of urethan-anesthetized female rats. Administration of CCK-8 (20 micrograms/kg iv) increased oxytocin contents in 30-min microdialysates sampled simultaneously within the SON (1.8-fold) and blood (2.4-fold, both P < 0.05) compared with prestimulation levels. In another experiment, after bilateral administration of CCK-8 directly into the SON (10 ng/0.5 microliter) via a microdialysis/infusion probe, oxytocin contents in dialysates sampled from the left and right SON were increased 2.3- and 1.7-fold (P < 0.05), respectively. In simultaneously sampled dialysates from the jugular vein, oxytocin content increased 2.3-fold (P < 0.05). In contrast, oxytocin in dialysates sampled outside the hypothalamic nuclei was not altered by systemic or central CCK-8. The direct infusion of CCK-8 into both SON increased the release of vasopressin within the SON 1.7-fold (P < 0.05) but failed to significantly change vasopressin release into blood. The present findings show a coordinated regulation of intranuclear and systemic release of oxytocin in response to systemic and central CCK-8 and provide further evidence for a possible involvement of endogenous oxytocin in the complex regulation of ingestive and reproductive behaviors induced by CCK-8 at the brain level.

Continuously elevated concentrations of oxytocin during milking are necessary for complete milk removal in dairy cows

The importance of elevated concentrations of oxytocin (OT) during the entire milking period was investigated in seven primiparous dairy cows with inherent disturbed milk ejection and in sixteen healthy cows with disturbed milk ejection induced by placing them in an operating theatre. Disturbance of milk removal in both groups has previously been demonstrated to be exclusively due to central blockage of the expected OT release in response to teat stimulation and milking. However, milk ejection can be induced by exogenous OT. OT (0.2 i.u.) was injected i.v. before milking and 49 +/- 6% of the total milk was removed. When plasma OT decreased, milk flow stopped. In response to a second and third injection of 0.2 i.u. OT, 30 +/- 4 and 7 +/- 2% of the milk were removed respectively. The remaining milk was removed with 10 i.u. OT. The lag time from injection of OT to the start of milk flow was inversely correlated with the amount of milk actually removed in response to the OT injection. If 0.2 i.u. OT was injected during intramammary pressure (IMP) recording, IMP immediately increased to its maximum value. After 2.5 +/- 0.3 min, IMP decreased to an intermediate IMP (between preinjection and maximum IMP). After two additional injections of 0.2 i.u. OT and after injection of 0.5 i.u. OT, IMP increased to a similar maximum. However, after injection of 0.5 i.u. OT, maximum IMP lasted longer (2.9 +/- 0.3 min; P < 0.05) than after injections of 0.2 i.u. If OT was continuously infused (0.15 i.u./min) during milking, milk flow lasted until the udder was completely emptied. IMP increased during OT infusion to a maximum which remained stable until infusion was stopped after 10 min. The same IMP maximum was reached after the first individual OT injection (0.2 i.u.), but when plasma OT decreased towards basal concentrations, milk flow ceased and IMP decreased to an intermediate level. Thus continuously elevated OT concentrations such as those during infusion or during normal milking are necessary for complete milk removal.

Opioids influence neurohypophysial but not central oxytocin release following direct hyperosmotic stimulation of the supraoptic nucleus in urethane-anaesthetised rats

Microdialysis was used to apply an osmotic stimulus (0.5 M NaCl-aCSF) into both supraoptic nuclei (SON) to investigate the role of endogenous opioid peptides in the control of both central and peripheral oxytocin release in response to this stimulus. There were no differences in central peptide release during direct hyperosmotic stimulation between groups of rats given either vehicle, morphine (5 mg/kg) or naloxone (5 mg/kg) intravenously. Naloxone potentiated oxytocin release into blood; this suggests that endogenous opioid peptides at the level of the neurohypophysis, but not in the SON are important modulators of oxytocin release to this stimulus. However morphine blocked oxytocin release into blood indicative of a central inhibitory action on the firing rate of oxytocin neurones, contrasted with insensitivity to morphine of oxytocin secretion from the dendrites stimulated directly by hyperosmolarity.

Stimulation of oxytocin release in the lactating rat by a central interaction of alpha 1-adrenergic and alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid-sensitive excitatory amino acid mechanisms.

These studies tested for a facilitatory interaction between noradrenergic and excitatory amino acid mechanisms controlling oxytocin (OT) release in the lactating rat. Lactating females were cannulated in the supraoptic nucleus of the hypothalamus (SON) or into the third ventricle and treated with the alpha 1-agonist phenylephrine (PHE) or the glutamate receptor agonist alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), either alone or together. Treatment with PHE increased plasma OT dose dependently after microinjection into the SON area; strong stimulation also occurred after third ventricle injection of the drug. AMPA caused dose-dependent increases in plasma OT after SON injection. Coinjection of an ineffective or submaximally effective dose of AMPA and a submaximally stimulating dose of PHE produced synergistic OT discharges. OT release in response to the combination of PHE plus AMPA could be abolished by pretreatment/cotreatment with either an alpha 1-adrenergic antagonist or an AMPA receptor antagonist. Moreover, the OT secretory response to the alpha 1-adrenergic agonist PHE alone was attenuated by blockade of AMPA receptors, whereas the OT secretory response to the glutamate agonist AMPA alone was attenuated by blockade of alpha 1-adrenergic receptors. These findings suggest an interaction between norepinephrine and glutamate that may involve pre- and/or postsynaptic mechanisms. As disruption of either noradrenergic or glutamatergic mechanisms is known to impair suckling-induced OT release, the cooperative action of transmitters active at alpha 1-adrenergic and AMPA receptors may be important for the milk ejection reflex.

Stimulation of oxytocin release in the lactating rat by a central interaction of alpha 1-adrenergic and alpha-amino-3-hydroxy-5- methylisoxazole-4-propionic acid-sensitive excitatory amino acid mechanisms

These studies tested for a facilitatory interaction between noradrenergic and excitatory amino acid mechanisms controlling oxytocin (OT) release in the lactating rat. Lactating females were cannulated in the supraoptic nucleus of the hypothalamus (SON) or into the third ventricle and treated with the alpha 1-agonist phenylephrine (PHE) or the glutamate receptor agonist alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), either alone or together. Treatment with PHE increased plasma OT dose dependently after microinjection into the SON area; strong stimulation also occurred after third ventricle injection of the drug. AMPA caused dose-dependent increases in plasma OT after SON injection. Coinjection of an ineffective or submaximally effective dose of AMPA and a submaximally stimulating dose of PHE produced synergistic OT discharges. OT release in response to the combination of PHE plus AMPA could be abolished by pretreatment/cotreatment with either an alpha 1-adrenergic antagonist or an AMPA receptor antagonist. Moreover, the OT secretory response to the alpha 1-adrenergic agonist PHE alone was attenuated by blockade of AMPA receptors, whereas the OT secretory response to the glutamate agonist AMPA alone was attenuated by blockade of alpha 1-adrenergic receptors. These findings suggest an interaction between norepinephrine and glutamate that may involve pre- and/or postsynaptic mechanisms. As disruption of either noradrenergic or glutamatergic mechanisms is known to impair suckling-induced OT release, the cooperative action of transmitters active at alpha 1-adrenergic and AMPA receptors may be important for the milk ejection reflex.

Central stimulation of oxytocin release in the lactating rat: interaction of neuropeptide Y with alpha-1-adrenergic mechanisms

The possible cooperation of neuropeptide Y (NPY) and alpha-1-adrenergic mechanisms in the release of oxytocin (OT) in conscious, nonsuckled lactating rats was examined following microinjections of NPY and its analogs and/or alpha-adrenergic drugs into the supraoptic nucleus (SON) or anterior paraventricular nucleus/anterior commissural nucleus (PVN/ACN). The alpha-1-adrenergic agonist phenylephrine dose dependently increased plasma OT after injection into the SON or the PVN/ACN, and this was prevented by treatment with the specific alpha-alpha-1-adrenergic receptor antagonist prazosin, but not by the alpha-2 antagonist rauwolscine. The alpha-2-adrenergic agonist clonidine did not increase plasma OT. Injection of NPY or of the related peptide YY (PYY) alone into the SON or the PVN/ACN also dose dependently increased plasma OT; this was also significantly attenuated by prazosin. Plasma OT responses to NPY and PYY differed significantly in dynamics and duration, which may be related to large differences found in the patterns of displaceable binding of [125I]NPY and [125I]PYY to hypothalamic membranes. The stimulatory action of NPY was mimicked by a preferential Y-1 receptor agonist, but not by an agonist of the Y-2 NPY receptor. Coinjection of NPY or PYY and phenylephrine into either the SON or the PVN/ACN area produced a greater than additive discharge of OT, especially in the SON. This increase was mostly due to a markedly enhanced initial release of OT, and was also completely eliminated by prazosin. The NPY-alpha-1 interaction in stimulating plasma OT was not mediated by direct binding of the peptides to alpha-1-adrenergic receptor sites. These results indicate that 1) the stimulatory noradrenergic influence on OT secretion in the lactating rat is mediated by the alpha-1 adrenergic receptor via an action in the PVN/ACN and SON; 2) NPY also stimulates OT secretion in the lactating rat through the Y-1 receptor subtype in the PVN/ACN and SON; 3) NPY markedly enhances the OT secretory responses to alpha-1 receptor stimulation, particularly in the SON. The cooperative stimulation by NE and NPY may be of physiological importance in mediating the episodic release of OT in response to suckling.

Central stimulation of oxytocin release in the lactating rat: interaction of neuropeptide Y with alpha-1-adrenergic mechanisms.

The possible cooperation of neuropeptide Y (NPY) and alpha-1-adrenergic mechanisms in the release of oxytocin (OT) in conscious, nonsuckled lactating rats was examined following microinjections of NPY and its analogs and/or alpha-adrenergic drugs into the supraoptic nucleus (SON) or anterior paraventricular nucleus/anterior commissural nucleus (PVN/ACN). The alpha-1-adrenergic agonist phenylephrine dose dependently increased plasma OT after injection into the SON or the PVN/ACN, and this was prevented by treatment with the specific alpha-alpha-1-adrenergic receptor antagonist prazosin, but not by the alpha-2 antagonist rauwolscine. The alpha-2-adrenergic agonist clonidine did not increase plasma OT. Injection of NPY or of the related peptide YY (PYY) alone into the SON or the PVN/ACN also dose dependently increased plasma OT; this was also significantly attenuated by prazosin. Plasma OT responses to NPY and PYY differed significantly in dynamics and duration, which may be related to large differences found in the patterns of displaceable binding of [125I]NPY and [125I]PYY to hypothalamic membranes. The stimulatory action of NPY was mimicked by a preferential Y-1 receptor agonist, but not by an agonist of the Y-2 NPY receptor. Coinjection of NPY or PYY and phenylephrine into either the SON or the PVN/ACN area produced a greater than additive discharge of OT, especially in the SON. This increase was mostly due to a markedly enhanced initial release of OT, and was also completely eliminated by prazosin. The NPY-alpha-1 interaction in stimulating plasma OT was not mediated by direct binding of the peptides to alpha-1-adrenergic receptor sites. These results indicate that 1) the stimulatory noradrenergic influence on OT secretion in the lactating rat is mediated by the alpha-1 adrenergic receptor via an action in the PVN/ACN and SON; 2) NPY also stimulates OT secretion in the lactating rat through the Y-1 receptor subtype in the PVN/ACN and SON; 3) NPY markedly enhances the OT secretory responses to alpha-1 receptor stimulation, particularly in the SON. The cooperative stimulation by NE and NPY may be of physiological importance in mediating the episodic release of OT in response to suckling.

Central oxytocin inhibition of angiotensin-induced salt appetite in rats.

In several models of salt appetite in the rat, stimulated NaCl intake can be severely blunted by treatments associated with pituitary release of oxytocin (OT). Central administration of the potent dipsogen angiotensin II (ANG II) is known to elicit a limited salt appetite as well as thirst, but it has also been reported to stimulate pituitary OT secretion. These results suggest the possibility that the expression of ANG II-induced salt appetite in rats may be inhibited by a simultaneous central release of OT in response to this stimulus. To investigate this possibility, rats were given intracerebroventricular injections of OT-receptor antagonists before administration of 5 ng ANG II intracerebroventricularly in a 1-h two-bottle (water and 0.3 M NaCl) drinking test. This pretreatment resulted in a three- to fourfold potentiation of ANG II-induced saline ingestion, which was most prominent during the first 15 min of the test. OT-receptor antagonism did not, however, interfere with the dipsogenic properties of ANG II, nor did it stimulate saline ingestion alone in the absence of ANG II. Immunocytochemical studies demonstrated that central administration of ANG II at this dose caused pronounced c-fos expression in hypothalamic magnocellular OT and vasopressin neurons and also in OT neurons in parvocellular subdivisions of the paraventricular nucleus. These results therefore demonstrate that central administration of small doses of ANG II activates both magnocellular and parvocellular OT neurons in rats and indicate that some of the activated central OT pathway(s) may mediate an inhibitory effect that limits the salt ingestion induced by this treatment.

Central Somatostatin Inhibits Cholecystokinin‐lnduced Oxytocin Secretion in Conscious Rats

Recent studies have demonstrated the presence of fibres immunoreactive for somatostatin-28 (SS-28), which originate in the brainstem and selectively innervate the magnocellular oxytocin (OT) cells of the supraoptic nucleus. The potential physiological relevance of this pathway was investigated in the present study by measuring plasma OT levels in response to intraperitoneal administration of cholecystokinin in conscious male rats pretreated with intracerebroventricular injections of either SS-28 or artificial cerebrospinal fluid. Cholecystokinin treatment produced the expected marked rise in plasma OT levels in control rats pretreated intracerebroventricularly with artificial cerebrospinal fluid. However, this response was markedly blunted by prior intracerebroventricular administration of SS-28, even though SS-28 itself had no effect on basal plasma OT levels, nor did it impair OT release in response to hypertonic saline injection. These results demonstrate that centrally injected SS-28 can selectively block cholecystokinin-stimulated release of OT in rats, and support an inhibitory role for this peptide in brainstem-mediated neurohypophysial hormone secretion. Central SS-28 administration also elicited up to 3-fold increases in the amount of food ingested in 1 h by previously sated rats. These observations suggest the possibility that endogenous SS-28 may be involved in stimulating food intake in rats, and establish the basis for future studies to clarify the role of this neuropeptide in controlling ingestive behaviours.

Morphine and corticotrophin-releasing factor potentiate maternal acceptance in multiparous ewes after vaginocervical stimulation

The effects of intracerebroventricular infusions of morphine, oxytocin, and corticotrophin-releasing factor (CRF) on maternal behaviour alone, or in conjunction with vaginocervical stimulation were determined in both nulliparous and multiparous ovariectomized ewes, primed with oestrogen for 3 days proir to testing. Both plasma and cerebrospinal fluid levels of oxytocin were measured under similar conditions, following CRF and morphine treatments. In nulliparous ewes, i.c.v. oxytocin and morphine reduced rejection behaviours, but neither these treatments nor vaginocervical stimulation promoted proceptive acceptance behaviour. Ewes that were maternally experienced showed increases in acceptance and a reduction of rejection behaviours following vaginocervical stimulation or i.c.v. oxytocin. Morphine and CRF potentiated the effects of vaginocervical stimulation on these behaviours. No treatment influenced oxytocin release per se, but i.c.v. morphine increased both peripheral and central release of oxytocin in response to vaginocervical stimulation. The results show that maternal experience is essential for oxytocin to promote proceptive behaviours and that morphine and CRF potentiate the effects of vaginocervical stimulation on acceptance behaviour. Since morphine also potentiated the release of oxytocin in response to vaginocervical stimulation it is difficult to separate the relative contribution of direct versus indirect effects of opiates in potentiating maternal bonding.

Stress‐Induced Oxytocin Release in the Rat After Lesion of the Paraventricular Nuclei; Possible Deficiency of Corticotrophin‐Releasing Factor

Abstract Oxytocin is released under stressful conditions and corticotrophin-releasing factor (CRF) is known to be involved in mediating general 'stress responses'. We therefore examined whether CRF neurons in the paraventricular nucleus participate in the stress-induced oxytocin release in the rat. CRF (0.02 to 2 nmol) injected into the third ventricle produced a dose-dependent rise in the plasma oxytocin concentration. The oxytocin release induced by CRF occurred without a change in blood pressure, and was not affected by dexamethasone pretreatment, which prevents adrenocorticotrophin release following CRF injection. Lesioning of the paraventricular nucleus reduced oxytocin release by immobilization stress, but did not alter the release of oxytocin in response to osmotic stimulation induced by intraperitoneal injection of hypertonic saline. Anti-CRF serum injection into the third ventricle reduced delayed oxytocin response to immobilization stress. These results are consistent with the hypothesis that CRF neurons in the paraventricular nucleus are involved in the oxytocin release during immobilization stress in the rat.

Ablation of the region anterior and ventral to the third ventricle (AV3V region) in the rat does not abolish the release of oxytocin in response to systemic cholecystokinin

The effect of peripheral administration of cholecystokinin octapeptide (CCK8) on release of oxytocin and vasopressin in the anaesthetized rat was investigated in sham-lesioned rats and in rats which had received electrolytic ablation of the region anterior and ventral to the third ventricle (AV3V region). CCK8 evoked a repeatable and dose-dependent release of oxytocin, but not vasopressin, into the systemic circulation of both sham and lesioned rats, confirming that in the rat CCK8 is a selective stimulus for oxytocin release, and showing that this release is not significantly impaired by lesions of the AV3V region.

Inhibition of suckling-induced milk ejections in the lactating rat by delta 9-tetrahydrocannabinol.

The effect of delta 9-tetrahydrocannabinol (THC) on suckling-induced oxytocin release was investigated by recording intramammary pressure changes in suckled rats treated iv with THC (0.5 mg/kg BW) or vehicle. Latency to the first posttreatment milk ejection and posttreatment milk ejection intervals and pressure wave amplitudes were compared between THC- and vehicle-treated rats. Before treatment, intervals between milk ejections averaged 6.5 +/- 1.3 (+/- SE) and 7.0 +/- 0.7 min for vehicle- and THC-treated groups, respectively. Vehicle injections did not alter the frequency of milk ejections, which continued at an overall mean interval of 7.6 +/- 0.7 min after treatment. In contrast, THC treatment was followed by a transient suspension of milk ejections, with a latency of 59.3 +/- 7.4 min before the first posttreatment milk ejection was recorded (P less than 0.001). Intervals between subsequent ejections averaged 15.3 +/- 2.0 to 16.1 +/- 1.3 min and were lengthened relative to corresponding intervals in vehicle-treated animals (P less than 0.05). The amplitudes of pressure waves were not significantly affected by treatment. Oxytocin (0.5 mU) injections 10 or 30 min after THC treatment evoked abrupt increases in intramammary pressure, indicating continued responsiveness of the mammary gland to oxytocin stimulation. These data suggest that THC interferes with the release of oxytocin in response to suckling. To our knowledge, this provides the first evidence that THC inhibits posterior pituitary function.